Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1852044 (
HS3
)
171
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Heparan sulfate (HS) is a highly heterogeneous polysaccharide implicated in many important biological processes. Our previous work has demonstrated that a particular affinity-selected HS (referred to henceforth as "HS3") is capable of enhancing the osteogenic effects of
bone morphogenetic protein 2
(
BMP2
). Here, we gamma-irradiated HS with 26 kGy of ionizing radiation to determine how this affected the structure, composition, and function. Initial structural studies were performed on a commercial preparation of HS as a proof-of-concept. Gamma irradiation of this HS preparation did not significantly alter its structure or composition compared to nonirradiated material, as demonstrated by proton nuclear magnetic resonance spectroscopy, molecular weight analysis using size exclusion chromatography, and disaccharide compositional analysis. When
HS3
was gamma irradiated, no significant effect on binding affinity toward
BMP2
was observed, based on competitive surface plasmon resonance and differential scanning fluorimetry assays. Furthermore, irradiation did not significantly affect
HS3
's ability to synergistically enhance the osteogenic effects of
BMP2
in vitro; as measured by the relative abundance of osteogenic transcripts in transdifferentiating C2C12 murine myoblasts. Additionally, no significant differences were observed in the levels of alkaline phosphatase (ALP) or calcium deposition in C2C12s treated with
BMP2
, together with the irradiated, or nonirradiated
HS3
. Irradiation of
HS3
incorporated into collagen type I sponges did not affect its ability to enhance
BMP2
-mediated ALP expression in C2C12 cells. Our data confirm that gamma irradiation is a cost-effective and viable solution for the sterilization of HS species that allows the retention of its structure and biological function. The work suggests an effective way to incorporate clinically compatible HS species into orthotic implants, scaffolds, and other medical devices for use in the treatment of a range of diseases and disorders.
...
PMID:Retention of the Structure and Function of Heparan Sulfate Biomaterials After Gamma Irradiation. 2894 28
Bone morphogenetic protein 2
(
BMP2
)-induced bone regeneration is most efficacious when a carrier can deliver the growth factor into the defect site while minimizing off-target effects. The control of
BMP2
release by such carriers is proving one of the most critical aspects of
BMP2
therapy. Thus, increasing numbers of biomaterials are being developed to satisfy the simultaneous need for sustained release, reduced rates of degradation and enhanced activity of the growth factor. Here we report on a biomimetic scaffold consisting of bovine collagen type I, bone granules (Intergraft
TM
), and heparan sulfate with increased affinity for
BMP2
(
HS3
). The
HS3
and collagen were complexed and then crosslinked via a simple dehydrothermal method. When loaded with a clinically relevant amount of
BMP2
(1.25 mg/cc), the
HS3
-functionalised scaffolds were able to retain up to 58% of the initial amount of
BMP2
over 27 days, approximately 3-times higher than scaffolds without
HS3
. The bioactivity of the retained
BMP2
was confirmed by gene expression in myoblasts cells (C2C12) cultured on the scaffolds under osteogenic stimulation. Together these data demonstrate the efficacy of
HS3
as a material to improve the performance collagen/bone granule-based scaffolds.
...
PMID:A biomimetic collagen-bone granule-heparan sulfate combination scaffold for BMP2 delivery. 3303 40